The Cerebral Palsy drugs in development market research report provides comprehensive information on the therapeutics under development for Cerebral Palsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Cerebral Palsy. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Cerebral Palsy and features dormant and discontinued products.
GlobalData tracks 18 drugs in development for Cerebral Palsy by 16 companies/universities/institutes. The top development phase for Cerebral Palsy is preclinical with seven drugs in that stage. The Cerebral Palsy pipeline has 16 drugs in development by companies and two by universities/ institutes. Some of the companies in the Cerebral Palsy pipeline products market are: Argent BioPharma, Hope Biosciences and FamiCord Group.
The key targets in the Cerebral Palsy pipeline products market include Cannabinoid Receptor 2, Cannabinoid Receptor 1, and Synaptosomal Associated Protein 25.
The key mechanisms of action in the Cerebral Palsy pipeline product include Cannabinoid Receptor 1 Agonist with three drugs in Preclinical. The Cerebral Palsy pipeline products include nine routes of administration with the top ROA being Intravenous and three key molecule types in the Cerebral Palsy pipeline products market including Cell Therapy, and Small Molecule.
Cerebral Palsy overview
Cerebral palsy is a group of disorders that can involve brain and nervous system functions, such as movement, learning, hearing, seeing, and thinking. Symptoms include muscles that are very tight and do not stretch, abnormal walk (gait), arms tucked in toward the sides, knees crossed or touching, legs make scissors movements, walking on the toes, speech problems (dysarthria), hearing or vision problems, and pain. Treatment includes anticonvulsants and muscle relaxants.
For a complete picture of Cerebral Palsy’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
